Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era.
Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era.
复制标题
DOI：
10.1002/bjs.10809
复制
发表时间：
2018-07
期刊：
影响因子：
--
通讯作者：
de Wilt JHW
中科院分区：
文献类型：
--
作者：
van der Graaf WTA;Tielen R;Bonenkamp JJ;Lemmens V;Verhoeven RHA;de Wilt JHW
在一个以诊断和治疗的进步而闻名的时代，研究了新诊断的胃肠道间质瘤（GIST）患者的发病率、治疗和结局。从荷兰癌症登记处检索了全国范围的基于人群的数据。纳入了2001年至2012年期间诊断的所有GIST患者。研究了主要治疗，定义为诊断后前6-9个月内的任何治疗。根据欧洲标准人群计算年龄标准化发病率。通过计算估计的年百分比变化（EAPC）来评估发病率的变化。使用相对生存期计算生存期，随访时间至2017年1月。共有1749例患者（54.0%为男性，中位年龄66岁）被诊断为GIST。非转移性GIST的发生率从2001年的3.1/百万人年增加到2012年的7.0/百万人年; EAPC为7.1（95% c.i. 4.1 ~ 10.2%（P <0.001）。2001年和2012年，原发性转移性GIST的发生率均为1.3/百万人年。5年相对存活率从2001-2004年的71.0%上升到2009-2012年的81.4%。女性比男性有更好的结果。总体而言，原发性转移性GIST患者的5年相对生存率为48.2（95% c.i. 42.0至54.2）%，而非转移性GIST患者为88.8（86.0至91.4）%。这项基于人群的全国性研究发现，荷兰GIST的发病率约为每百万人年8例。五分之一的患者出现转移性疾病，但在伊马替尼时代，所有GIST患者的相对生存率随时间推移显著改善。手术可提高生存率
The incidence, treatment and outcome of patients with newly diagnosed gastrointestinal stromal tumour (GIST) were studied in an era known for advances in diagnosis and treatment. Nationwide population‐based data were retrieved from the Netherlands Cancer Registry. All patients with GIST diagnosed between 2001 and 2012 were included. Primary treatment, defined as any treatment within the first 6–9 months after diagnosis, was studied. Age‐standardized incidence was calculated according to the European standard population. Changes in incidence were evaluated by calculating the estimated annual percentage change (EAPC). Relative survival was used for survival calculations with follow‐up available to January 2017. A total of 1749 patients (54·0 per cent male and median age 66 years) were diagnosed with a GIST. The incidence of non‐metastatic GIST increased from 3·1 per million person‐years in 2001 to 7·0 per million person‐years in 2012; the EAPC was 7·1 (95 per cent c.i. 4·1 to 10·2) per cent (P < 0·001). The incidence of primary metastatic GIST was 1·3 per million person‐years, in both 2001 and 2012. The 5‐year relative survival rate increased from 71·0 per cent in 2001–2004 to 81·4 per cent in 2009–2012. Women had a better outcome than men. Overall, patients with primary metastatic GIST had a 5‐year relative survival rate of 48·2 (95 per cent c.i. 42·0 to 54·2) per cent compared with 88·8 (86·0 to 91·4) per cent in those with non‐metastatic GIST. This population‐based nationwide study found an incidence of GIST in the Netherlands of approximately 8 per million person‐years. One in five patients presented with metastatic disease, but relative survival improved significantly over time for all patients with GIST in the imatinib era. Surgery improves survival
登录
查看更多内容
影响因子：
45.3
作者：
Blanke, Charles D.;Rankin, Cathryn;Borden, Ernest C.
通讯作者：
Borden, Ernest C.
影响因子：
11.5
作者：
Cassier, Philippe A.;Fumagalli, Elena;Hohenberger, Peter
通讯作者：
Hohenberger, Peter
影响因子：
3.2
作者：
Choi, Audrey H.;Hamner, John B.;Kim, Joseph
通讯作者：
Kim, Joseph
DOI：
10.1016/s0140-6736(12)61857-1
发表时间：
2013-01-26
期刊：
Lancet (London, England)
影响因子：
--
作者：
Demetri GD;Reichardt P;Kang YK;Blay JY;Rutkowski P;Gelderblom H;Hohenberger P;Leahy M;von Mehren M;Joensuu H;Badalamenti G;Blackstein M;Le Cesne A;Schöffski P;Maki RG;Bauer S;Nguyen BB;Xu J;Nishida T;Chung J;Kappeler C;Kuss I;Laurent D;Casali PG;GRID study investigators
通讯作者：
GRID study investigators
影响因子：
45.3
作者：
Joensuu, Heikki;Eriksson, Mikael;Reichardt, Peter
通讯作者：
Reichardt, Peter